"10.1371_journal.pone.0107595","plos one","2014-09-15T00:00:00Z","Willy Ssengooba; Lydia Nakiyingi; Derek T Armstrong; Frank G Cobelens; David Alland; Yukari C Manabe; Susan E Dorman; Jerrold J Ellner; Moses L Joloba","Department of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda; Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Global Health and Amsterdam Institute of Global Health and Development, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; KNCV Tuberculosis Foundation, The Hague, Netherlands; Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, United States of America","Conceived and designed the experiments: WS. Performed the experiments: WS LN MLJ DTA DA. Analyzed the data: WS FGC. Contributed reagents/materials/analysis tools: MLJ JJE SED YCM. Contributed to the writing of the manuscript: WS LN DTA FGC DA YCM SED JJE MLJ.","WS, FGC, NL, DA, YM, SED, JJE and MJ have declared that no competing interests exists. David Alland (DA) and DAs laboratory receive royalties from licensing fees for the use of molecular beacons in the Cepheid XpertMTB/RIF assay. DAs personal loyalties with the assay are capped at $4,999 per year, and royalties payable to DAs laboratory are at $50,000 per year. DA also received a research grant from Cepheid. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","09","Willy Ssengooba","WS",9,FALSE,1,5,2,NA,TRUE,TRUE,FALSE,0,NA,FALSE
